Tuesday July 14, 2020

Elan may make EDT a stand-alone firm

Pharmaceutical company Elan has said that ‘‘it might make sense’’ to strip off its $1.5 billion development and manufacturing division from its biopharmaceutical business.

26th April, 2008

Pharmaceutical company Elan has said that ‘‘it might make sense’’ to strip off its $1.5 billion development and manufacturing division from its biopharmaceutical business.

The comments follow speculation that the company is preparing to sell off Elan Drug Technology (EDT). Chief financial officer Shane Cooke told analysts that EDT could benefit from being a standalone business.

‘‘If you look at the future potential for both businesses, EDT could benefit from a focus...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

The best writing and and the biggest stories of 2019 from the Business Post

Richie Oakley | 6 months ago

Denis O’Brien is back in court, residents continue to fight the Council on halting site and a row surfaces in government over rent control proposals

Leanna Byrne | 4 years ago